1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is the most common form of dementia \[[@B1], [@B2]\], with the dominant presentation of a progressive decline in cognitive functioning beyond what is expected from normal aging. The neurodegeneration in AD may be caused by deposition of amyloid beta-peptide in plaques or formation of neurofibrillary tangle in brain tissue \[[@B1], [@B2]\]. Although little is known of the actual cause of AD, many of its symptoms are generally accepted to be related to a cholinergic deficit in the cerebral cortex and other areas of the brain \[[@B3]--[@B5]\]. Acetylcholinesterase (AChE) inhibitors, which inhibit the acetylcholinesterase enzyme from breaking down acetylcholine and thereby increasing the level and duration of the neurotransmitter acetylcholine activity, have been proven to be an effective therapy for AD \[[@B6]--[@B11]\]. Pharmacoeconomic studies have demonstrated that therapies can postpone dementia from progressing to more severe stages and may also result in economic benefits for patients\' families and caregivers, as well as for society \[[@B12]--[@B16]\]. However, clinicians have argued that AChE inhibitors have an effect on a subgroup of only 25--50% of AD patients \[[@B17]--[@B19]\], which cannot be identified objectively prior to therapy. Furthermore, the time scale for measuring the effect of AChE inhibitors can last anywhere between several months to several years.

Recently, numerous studies have attempted to identify a prognostic predictor of AD by using artificial neural networks \[[@B20]\], brain magnetic resonance imaging (MRI) \[[@B18], [@B21]\], single-photon emission computed tomography (SPECT) \[[@B22]\], and cognitive function tests \[[@B23]\]. However, technical dependence, high costs, contrast-agent related allergies, and potential exposure to radionuclide irradiation have limited their clinical application. On the other hand, numerous forms of quantitative electroencephalographic (EEG) analyses have been used to elucidate the characteristics of EEGs to enhance diagnostic power with the assistance of signal processing, suggesting a potential objective tool in the evaluation of AD \[[@B24]--[@B36]\]. The surface EEG represents the electrical activity of innumerable cortical neurons, which determine the fundamental patterns that indicate the interaction between various mechanisms with multiple and spatial scales. As it is quite difficult to explain the underlying neurophysiology mechanism, nonlinear based methods have recently been used more frequently to explore the EEG activity \[[@B37], [@B38]\]. The majority of the studies that have used nonlinear methods showed the loss of the complexity of EEG signals to be correlated with the severity of the dementia \[[@B31], [@B32], [@B34], [@B35]\]. However, it is difficult to determine which specific physiological mechanism degrades the complexity of the EEG, and, as a result, clinicians lack information regarding the effective responder to AChE inhibitors in AD patients.

In light of fundamental nonlineal theory, biological signals represent the outcome of the nonlinear interactions between different processes at multiple temporal and spatial scales, including EEGs and electrocardiograms (ECG). With this understanding, some studies proposed a careful examination of changes in nonlinear indices with scales. The most well-known of these changes is the crossover phenomenon of the fractal correlation exponents between short and long time scales in the detrended fluctuation analysis (DFA) \[[@B39]\] of heart-rate dynamics. The short-term exponent is understood to be determined mostly by cardiorespiratory interaction \[[@B39], [@B40]\]. Recently, the studies of activity fluctuation with aging and in AD \[[@B41], [@B42]\] determined that fractal correlations at certain scales (i.e., 1.5--8.0 hours) declined with age. These studies also determined that an age-independent AD effect further reduced the correlations at these scales, leading to the greatest reduction of the correlations in very old people with late-stage AD. This result closely resembles the loss of correlations at long time scales in suprachiasmatic nucleus- (SCN-) lesioned animals \[[@B43]\]. In addition to DFA, multiscale entropy (MSE) analysis, proposed by Costa et al. \[[@B44], [@B45]\], is a possible method for measuring the complexity of nonlineal signals at different temporal scales by means of an entropy-based algorithm. In our previous study, we proposed a detrending process \[[@B31], [@B46], [@B47]\] to attenuate the spurious influence caused by nonstationarity in the real world. This study also demonstrated many features of the scale function of entropy, including the slope of the scale function of entropy used to check the existence of fractal correlation (a negative slope indicates a greater number of random fluctuations corresponding to loss of interaction), which can assist with clinical classification \[[@B47]\]. For example, sympathetic and parasympathetic activities are correlated with MSE on different scales of the heartbeat sequence (scales 3--5 and 1--4 for sympathetic activity and parasympathetic activity, resp.) \[[@B46]\]. Furthermore, congestive heart failure patients without *β*-blocker therapy exhibit a very negative slope for MSE1--5, indicating the lack of interaction to be a result of respiratory regulation \[[@B40]\].

Tracing the activation of the neurotransmitter ACh, which is released from the presynaptic vesicles that are triggered by action potential (electrical impulse), diffused in the synapse, and then finally conjugated to the postsynaptic receptor (5--50 msec) \[[@B48]--[@B50]\], these activations are observed at different time scales, each of which may be studied using MSE analysis.

In this study, we hypothesize that some features, such as slope, of MSE analysis of EEG data can be associated with the therapy efficacy of AChE inhibitors in AD patients, relying on the ability of MSE to demonstrate different mechanisms with multiple temporal or spatial scales.

2. Materials and Methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

All participants in this study were diagnosed with dementia and enrolled from the neurological clinic at the National Yang Ming University Hospital. After screening for dementia, all participants received further medical, neurological, neuropsychological, and psychiatric assessments, as well as blood examinations. Neurological assessments for all participants included cerebral computed tomography (CT) scans to rule out intracranial pathology (i.e., brain tumors or stroke) that may have contributed to cognitive decline. Trained research assistants administered the Chinese version of the minimental state examination (MMSE) \[[@B51]\], which features a total score of 30. The clinical dementia rating (CDR) was also used to determine the severity of dementia after a neurologist conducted separate semistructured interviews with the patient and a knowledgeable informant. The scores are as follows: 0 for normal, 0.5 for questionable, 1 for mild, 2 for moderate, and 3 for severe \[[@B52]\]. AD was diagnosed according to the diagnostic criteria of the Diagnostic and Statistical Manual of Psychiatric Disorders, 4th revised \[[@B53]\]. EEG was not included as part of the routine workup.

The inclusion criteria for participation in the EEG study included (1) a diagnosis of probable AD based on the Diagnostic and Statistical Manual of Psychiatric Disorders, 4th revised (DSM-IV) criteria \[[@B53]\] and (2) a rating of either 1 or 2 on the CDR scale \[[@B52]\]. Patients with dementia that may have been caused by reasons other than AD, as determined by the patient\'s history, neurological examinations, imaging, and blood studies, were excluded from this study so as to ensure that alterations in EEGs were caused exclusively by AD. The research was approved by the institutional review board of National Yang-Ming University Hospital, Yi-Lan, Taiwan, a local community teaching hospital. Written informed consent was obtained from each participant prior to the study.

Seventeen newly diagnosed AD patients (9 men and 8 women, mean age 74.6 ± 7.4) were enrolled in this study, with an initial MMSE score of 18.8 ± 4.5. Two of these patients were moderately demented (CDR = 2), whereas the remaining 15 were mildly demented (CDR = 1). None of the patients received any antipsychotics prior to the first EEG. Each participant received the AChE inhibitor donepezil hydrochloride (Aricept) 5 mg/d for 12 months and follow-up MMSE 12 months after therapy.

2.2. EEG Recordings {#sec2.2}
-------------------

EEGs were recorded for all subjects. In accordance with International Federation of Clinical Neurophysiology (IFCN) standards for the digital recording of clinical EEG \[[@B54]\], the surface EEG signals were recorded using a digital EEG recorder (NicoletOne) from the 19 scalp loci of the international 10--20 system (channels Fp1, Fp2, F3, F4, C3, C4, P3, P4, O1, O2, F7, F8, T3, T4, T5, T6, Fz, Cz, and Pz), with all electrodes referenced to the bilateral ear (A1, A2) for 30 min. ECGs were recorded on a separate channel as a part of EEG recordings. The sample frequency was 256 Hz and the analog-to-digital converter digitalized resolution was 12 bits. All the patients remained awake in a relaxed state in order to undergo a 30 min eyes-closed EEG.

2.3. Signal Processing and Analysis: Multiscale Entropy Analysis {#sec2.3}
----------------------------------------------------------------

We adopted MSE as a complexity measure to feature digitalized EEG signals. Before conducting the analysis, one 30 sec artifact-free epoch EEG signal was selected by an experienced neurologist. Furthermore, empirical mode decomposition \[[@B55]\], which is considered superior to the traditional linear quantitative method to ascertain the intrinsic complexity, was utilized to remove the trend (\<1 Hz) from the signals as was also the case in our previous study \[[@B31]\]. The MSE method is comprised of the following two steps: (1) coarse-graining the signals into different time scales and (2) quantifying the degree of irregularity in each coarse-grained time series using sample entropy (SampEn) \[[@B56], [@B57]\].

### 2.3.1. Sampling Entropy (SampEn) {#sec2.3.1}

{*x* ~*i*~} = {*x* ~1~, *x* ~2~,..., *x* ~*i*~,..., *x* ~*N*~} represents a time series of data length *N*. The *m*-length vector extracted from time series {*x* ~*i*~} was defined by *u* ~*m*~(*i*) = {*x* ~*i*~, *x* ~*i*+1~,..., *x* ~*i*+*m*−1~} where *n* ~*i*~ ^*m*^(*r*) represents the number of vectors, *u* ~*m*~(*j*) that are close to the given vector, *u* ~*m*~(*i*). To obtain *n* ~*i*~ ^*m*^(*r*), we first defined the distance, *d*\[*u* ~*m*~(*i*), *u* ~*m*~(*j*)\] between the given vector *u* ~*m*~(*i*) and *u* ~*m*~(*j*) as the maximum absolute difference between their corresponding scalar elements, that is, *d*\[*u* ~*m*~(*i*), *u* ~*m*~(*j*)\] = max⁡~*k*=0,*m*−1~\[\|*x* ~*i*+*k*~ − *x* ~*j*+*k*~\|\]. Then, *n* ~*i*~ ^*m*^(*r*) was defined by counting the number of *u* ~*m*~(*j*) with *d*\[*u* ~*m*~(*i*), *u* ~*m*~(*j*)\]\|~*j*=1,*n*−*m*+1~ smaller than the threshold, *r*, a given prior. Note that here *j* ≠ *i*; that is, self-matches were not included to avoid the bias of ApEn \[[@B58]\]. The ratio of *n* ~*i*~ ^*m*^(*r*) to total number of*m*-vectors extracted from the time series was evaluated, and the result was denoted as *C* ~*r*~ ^*m*^(*i*). The above steps were repeated to find *C* ~*r*~ ^*m*^(*i*) from *i* = 1 to *i* = *N* − *m* + 1; then the natural logarithm of each *C* ~*r*~ ^*m*^(*i*) was calculated and then averaged over *i* to obtain *ϕ* ^*m*^(*r*). Theoretically, sample entropy \[[@B56], [@B57]\] is defined as SampEn(*m*, *r*) = *ϕ* ^*m*^(*r*) − *ϕ* ^*m*+1^(*r*). Note that the average of *C* ~*r*~ ^*m*^(*i*) can be regarded as the probability that any two vectors extracted from time series {*x* ~*i*~} are similar in some sense; therefore, *ϕ* ^*m*^(*r*) − *ϕ* ^*m*+1^(*r*) and conceptually represents the average of the natural logarithm of the conditional probability that the sequences that are close to each other for *m* consecutive data points will still be close to each other when one more point is given.

### 2.3.2. Multiscale Entropy (MSE) {#sec2.3.2}

SampEn is a statistical measure based on information theory used to quantify the irregularity of a sequence of data \[[@B56]--[@B58]\]. It examines a time series for occurrences of similar epochs of a preassigned length; similarity is determined with respect to whether the distance between epochs is under a tolerance *r* or not. More specifically, it calculates the negative natural logarithm of the conditional probability (i.e., those epochs) similar for *m* points that will remain so when one additional point is added to the subseries \[[@B56]--[@B58]\]. The higher the SampEn is, the more unpredictable the data sequence is. However, complicated systems typically generate highly irregular output \[[@B37]\] and also exhibit dynamically diverse tendencies on various time scales, including, for example, the coexistence of slow and fast phenomena. Although SampEn provides an adequate way of quantifying irregularities for physiological output, it is not sufficient alone to cope with the complex content for the purpose of physiological research. In contrast, MSE analysis, based on evaluating the sample entropy at multiple time scales, has proven useful in this regard. To recast a signal in another scale, the original series were segregated into blocks, where each block contained *n* data points. The mean value over each block then formed the coarse-grained time series at scale *n*. It is clear that the time series at coarse-grained scale 1 is identical to the original signal. Equipped with multiple scales, the MSE method can disclose the temporal structures as well as scale-dependent characteristics of signals.

### 2.3.3. Slope of MSE {#sec2.3.3}

In this study, the MSE value of each lead was calculated individually, which amounts to 380 values for each patient. Slopes of the mean value of MSE, averaged out of all leads, over scales 1--5 (Slope 1) and 6--20 (Slope 2) were estimated using the least-squares method (i.e., one Slope 1 and one Slope 2 for each patient). Throughout the analysis, we set *m* = 2 and *r* = 0.15 times the standard deviation of the processed signal, as was the case in our previous study \[[@B31]\].

2.4. Statistical Analyses {#sec2.4}
-------------------------

Based on the differences between the follow-up and the initial MMSE scores, the patients were divided into two groups: a responder group and a nonresponder group. A responder was identified as a patient whose follow-up MMSE score was greater than or equal to the initial score; patients whose follow-up MMSE scores were less than the initial score were classified as nonresponders.

Descriptive statistics were presented as means ± standard deviation (SD). SPSS (ver16.0) for Windows (SPSS Inc., Chicago, IL, USA) was used for analysis. Baseline demographic characteristics, including age, MMSE, CDR, and MSE of each lead, and Slope 1 and Slope 2 were coded as continuous variables. Other demographic characteristics, such as sex, were coded as dichotomous variables. All of these characteristics were treated as predicable variables for treatment response. Because of the small sample size in this study, a Mann-Whitney*U* test (instead of Student\'s*t*-test) was used to determine which factors were significant. A forward logistic regression, being a regression model in which the choice of predictive variables is carried out by an automatic procedure, which involves starting with no variables in the model, testing the addition of each variable using a chosen model comparison criterion, adding the variable (if any) that improves the model the most, and repeating this process until none improves the model was then used to calculate the odds ratio in the variants. All of the statistical tests were two-tailed and significance levels were set at a *P* value of less than 0.05.

By conducting the receiver operating characteristic (ROC) analysis and considering the optimal combination of sensitivity and specificity, we determined the best cut-off points. Likelihood ratios and positive and negative predictive values with 95% confidence intervals (CI) were assessed at each of the cut-off point levels.

3. Results {#sec3}
==========

Seven patients (3M/4F, mean age 76.1 ± 7.9) were categorized as responders and ten patients (6M/4F, mean age 73.5 ± 7.3) were categorized as nonresponders. There were no significant differences in age and gender between the patients in these two groups. The initial MMSE score in the responder group was 15.6 ± 5.1, and in the nonresponder group it was 20.9 ± 2.8 (*P* = 0.070). The MSE values in each lead were significantly higher in F7 MSE7, Fz MSE6, Fz MSE7, Fz MSE8, C4 MSE5, T4 MSE6, T4 MSE7, T4 MSE9, Pz MSE7, Pz MSE8, and O1 MSE7 ([Table 1](#tab1){ref-type="table"}). Slope 1 was 0.063 ± 0.038 for the responder group and 0.092 ± 0.071 for the nonresponder group (*P* = 0.333) ([Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Slope 2 was −0.008 ± 0.019 for the responder group and −0.03 ± 0.009 for the nonresponder group (*P* = 0.021) ([Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). After applying the forward logistic regression, only Slope 2 was preserved. The other factors, including the initial MMSE, were excluded.

The area under the ROC curve of Slope 2 ([Figure 2](#fig2){ref-type="fig"}) was 0.871 (95% CI = 0.69--1). The sensitivity was 85.7% and the specificity was 60%, while the cut-off value of Slope 2 was −0.024 ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

This pilot study demonstrated the potential of quantitative EEG, the slope of MSE, to predict the efficacy of AChE inhibitors in treating AD. When Slope 2 (MSE 6--20) is less than −0.024, therapy efficacy is relatively poor, with a sensitivity of 85.7% and specificity of 60%. However, the efficacy of AChE inhibitors in AD was affected by various factors, including antipsychiatric agents for behavior and psychiatric syndromes, other systemic disorders, hypertension, diabetes, and so on. Therefore, it is difficult to predict the efficacy of AChE inhibitors using a single biomarker, such as MSE in this study. However, this study can produce other findings, including whether or not the dosage of the AChE inhibitor is sufficient and whether we should try a form of combination therapy (i.e., AChE inhibitor and N-methyl-d-aspartate (NMDA) receptor antagonist) for patients with a very negative slope at the region with scales 6--20 (i.e., Slope 2).

Understanding the complexity at certain scales may correspond to the illness of specific physiology processes; furthermore, MSE analysis of EEG signals is a possible way to profile the cholinergic effect in cortex. [Figure 1](#fig1){ref-type="fig"} illustrates the maximum value of MSE which occurred at MSE6 (approximately 20 msec in the time scale) in nonresponders and almost a plateau from MSE5 to MSE10 (approximately 20 msec to 40 msec in the time scale) in responders. This indicates that time scales are compatible with the transfer time from the presynapse to the postsynapse, where the membranes are separated by a synaptic cleft that averages 20 to 50 nm (0.02 to 0.05 *μ*m) in width \[[@B50], [@B59]\] and lasts for approximately 15 msec \[[@B48]--[@B50]\]. Furthermore, it takes approximately 20 msec to break the ACh molecules from the binding receptor sites \[[@B48]\]. For the sampling rate of 256 Hz, the small (1--5) and large scales (6--20) of MSE could be associated with transfer time from the presynapse to postsynapse and binding time of ACh molecules, respectively. Therefore, the features of MSE1 to MSE5 are responsive to the amount of released ACh or the concentration of ACh in the synapse. In addition, the higher value in F7 MSE7, Fz MSE6, Fz MSE7, Fz MSE8, C4 MSE5, T4 MSE6, T4 MSE7, T4 MSE9, Pz MSE7, Pz MSE8, and O1 MSE7 in nonresponders may be attributed to the compensative release of ACh to maintain a similar cognitive activation as the responder. In the larger scales (\>12), the nonresponders have smaller values than the responders. However, this difference is not significant statistically ([Figure 1](#fig1){ref-type="fig"}), which suggests the poor binding ability of ACh to the receptor. On the other hand, the significantly negative slope (the region with scales over 20 msec) of the scale function of entropy for the nonresponders indicates the disrupted fractal pattern (i.e., more random fluctuations) and thus suggests the reduction of interaction in the neurological network (working at time scales over 20 msec). We can hypothesize that the slope of MSE in large time scales (*n* ≥ 6) is responsive to the Ach molecular binding ability or binding count; the nonresponders have lower ACh molecular binding ability or binding count and poor interaction in the neurological network. They therefore may require a higher dose of AChE inhibitors or other mechanism therapy, such as NMDA receptor antagonist, to improve clinical syndromes. A study by Escudero et al. \[[@B37]\] showed the slope of MSE in long time scale (*n* ≥ 6) is larger in normal control, which is compatible with our hypothesis.

Previous studies \[[@B37], [@B38]\] showed a higher complexity in demented patients in long time scales, which challenges the above hypothesis as the long time scales are related to the ACh molecular binding ability or binding counts. However, there have been some significant differences with regards to methods and study design, such as the severity of demented patients in this study and empirical mode decomposition (EMD) as a preprocessing to detrend the signals, which would produce better results in nonstationary physiology signals \[[@B31]\]. Nevertheless, other neurophysiological mechanisms might exist to explain both conditions.

The initial MMSE in the responders showed lower scales than that of the nonresponders (although not significant statistically), and this may be the reason why there is a higher response rate to AChE inhibitors among the responders. However, the usefulness of MMSE was excluded by following forward logistic regression. A previous study \[[@B23]\] showed no significant difference in pretreatment MMSE scores between responders and nonresponders, which is a result that is similar to the one in our study. In that same study, better visual-spatial motor ability, clock drawing, and tracking test results were also recorded among the responders. Therefore, the lower MMSE score among responders in this study does not explain the difference between responders and nonresponders.

MSE analyses of EEG data in this study disclose the different Slope 2 value in responders and nonresponders for AChE inhibitors, indicating an existing physiologic condition, which confirms our hypothesis regarding the neurotransmitter, Ach, or other nonlinear interactions between different processes at multiple temporal and spatial scales. More rigorous study is required to elucidate the physiological significance of the values and slopes of MSE. Due to a lack of other types of medication in this study, the application of predicting the efficacy with respect to different types of AChE inhibitors or NMDA antagonist is also uncertain. Lastly, although this study was limited by its small sample size, the statistical power was still high enough to support our findings.

5. Conclusion {#sec5}
=============

MSE analysis of EEG recordings can show characteristics both at short and at long time scales and provide a potential tool for predicting the efficacy of AChE inhibitors in AD. This nonlineal method improved EMD-based sampling entropy, which was introduced as an optimum method for evaluating embedded information in EEG and as an objective, noninvasive, and cost-effective tool for evaluating and monitoring AD patients \[[@B31]\], but not for providing enough information about the possible responder to the AChE inhibitor in AD.
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###### 

The demographic characteristics of two groups.

            Responder        Nonresponder    *P* value
  --------- ---------------- --------------- -----------
  Age       76.1 ± 7.9       73.5 ± 7.3      0.669
  Sex       3M/4F            6M/4F           0.601
  MMSE      15.9 ± 5.1       20.9 ± 2.8      0.070
  CDR       0.8 ± 0.6        1.2 ± 0.6       0.230
  Slope 1   0.063 ± 0.038    0.092 ± 0.071   0.475
  Slope 2   −0.008 ± 0.019   −0.03 ± 0.009   0.010^\*^
  F7 MSE7   1.85 ± 0.15      1.98 ± 0.10     0.043^\*^
  Fz MSE6   1.84 ± 0.26      2.04 ± 0.06     0.025^\*^
  Fz MSE7   1.87 ± 0.23      2.04 ± 0.08     0.043^\*^
  Fz MSE8   1.84 ± 0.21      2.01 ± 0.09     0.033^\*^
  C4 MSE5   1.84 ± 0.25      2.05 ± 0.10     0.043^\*^
  T4 MSE6   1.77 ± 0.21      1.99 ± 0.10     0.019^\*^
  T4 MSE7   1.79 ± 0.20      1.99 ± 0.12     0.033^\*^
  T4 MSE9   1.79 ± 0.22      2.00 ± 0.16     0.019^\*^
  Pz MSE7   1.92 ± 0.20      2.13 ± 0.10     0.010^\*^
  Pz MSE8   1.95 ± 0.17      2.13 ± 0.10     0.007^\*^
  O1 MSE7   1.89 ± 0.23      2.08 ± 0.10     0.033^\*^

Demographic characteristics of two groups, including age, sex, MMSE, CDR, Slope 1, Slope 2, and MSE values of each lead with significant differences in Mann-Whitney  *U* test. ^\*^Indication that the correlation is significant at the 0.05 level (2-tailed).

###### 

The raw data of two groups; MMSE as minimental status examination; CDR as clinical dementia rating.

  Group          Age   MMSE   CDR
  -------------- ----- ------ -----
  Nonresponder   65    25     1
  Nonresponder   80    19     1
  Nonresponder   81    20     1
  Nonresponder   61    24     1
  Nonresponder   80    21     1
  Nonresponder   73    24     1
  Nonresponder   71    16     1
  Nonresponder   67    21     1
  Nonresponder   81    19     1
  Nonresponder   76    20     1
  Responder      69    21     1
  Responder      67    21     1
  Responder      88    16     1
  Responder      71    14     1
  Responder      84    9      2
  Responder      79    10     2
  Responder      75    20     1
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